This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.
Is a Beat Likely for Intuitive Surgical (ISRG) in Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
UnitedHealth Group (UNH) Tops on Q1 Earnings, Reaffirms EPS View
by Zacks Equity Research
UnitedHealth Group (UNH) first-quarter earnings benefit from strong Optum and UnitedHealthcare business lines. Rising expenses partially offset the positives.
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
ITGR vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
by Zacks Equity Research
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
What's in Store for Thermo Fisher (TMO) in Q1 Earnings?
by Zacks Equity Research
Strength in Analytical Instrument and Laboratory Products and Services segments are likely to have driven Thermo Fisher's (TMO) first-quarter 2024 performance.
Will Elevance (ELV) Beat Q1 Earnings on Carelon Strength?
by Zacks Equity Research
The first-quarter results of Elevance (ELV) are likely to reflect higher product revenues and Commercial Individual membership growth.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
Can High Medical Costs Affect UnitedHealth's (UNH) Q1 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) first-quarter results are likely to reflect growth in premium levels and service revenues.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.
Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q1 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) first-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues and the number of people it served.
Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia
by Zacks Equity Research
Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.
Tenet Healthcare (THC) Soars 76% in a Year: What Lies Ahead?
by Zacks Equity Research
Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.
Here's Why Investors Should Hold Teladoc (TDOC) Stock Now
by Zacks Equity Research
Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
If You Invested $1000 in Edwards Lifesciences a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Delcath Systems (DCTH) delivered earnings and revenue surprises of 28.36% and 12.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Edwards Lifesciences (EW) This Year?
by Zacks Equity Research
Here is how Edwards Lifesciences (EW) and Avinger (AVGR) have performed compared to their sector so far this year.
Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock
by Zacks Equity Research
UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.
Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.
IQVIA (IQV) Up 5.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences (EW) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.